Asthika Goonewardene
Stock Analyst at Truist Securities
(1.15)
# 3,471
Out of 4,829 analysts
92
Total ratings
32.93%
Success rate
-17.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AUTL Autolus Therapeutics | Maintains: Buy | $11 → $10 | $1.32 | +657.58% | 4 | Apr 1, 2025 | |
| GMAB Genmab | Maintains: Buy | $50 → $45 | $19.36 | +132.44% | 14 | Mar 11, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $25 → $15 | $1.75 | +757.14% | 6 | Mar 3, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Hold | $32 → $7 | $4.03 | +73.91% | 3 | Jan 30, 2025 | |
| EXEL Exelixis | Maintains: Buy | $42 → $43 | $36.17 | +18.88% | 8 | Jan 27, 2025 | |
| IGMS IGM Biosciences | Maintains: Hold | $12 → $2 | $1.13 | +76.99% | 8 | Jan 10, 2025 | |
| BNTX BioNTech SE | Initiates: Buy | $172 | $92.87 | +85.22% | 1 | Jan 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $35 | $23.96 | +46.08% | 1 | Jan 8, 2025 | |
| ACLX Arcellx | Maintains: Buy | $87 → $136 | $57.55 | +136.32% | 5 | Nov 12, 2024 | |
| GILD Gilead Sciences | Maintains: Hold | $83 → $97 | $96.91 | +0.09% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $0.87 | +1,621.17% | 6 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 → $14 | $1.16 | +1,106.90% | 6 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $44 | $8.28 | +431.40% | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $88 | $31.78 | +176.90% | 1 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $69 → $88 | $40.90 | +115.16% | 2 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.26 | +217.46% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $0.77 | +2,353.83% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.32 | +2,722.20% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $1.30 | +2,976.92% | 4 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $0.61 | +4,326.96% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $13.23 | +807.03% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $1.67 | +3,492.81% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $0.45 | +3,263.23% | 4 | Aug 23, 2022 |
Autolus Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $1.32
Upside: +657.58%
Genmab
Mar 11, 2025
Maintains: Buy
Price Target: $50 → $45
Current: $19.36
Upside: +132.44%
Iovance Biotherapeutics
Mar 3, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $1.75
Upside: +757.14%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Hold
Price Target: $32 → $7
Current: $4.03
Upside: +73.91%
Exelixis
Jan 27, 2025
Maintains: Buy
Price Target: $42 → $43
Current: $36.17
Upside: +18.88%
IGM Biosciences
Jan 10, 2025
Maintains: Hold
Price Target: $12 → $2
Current: $1.13
Upside: +76.99%
BioNTech SE
Jan 10, 2025
Initiates: Buy
Price Target: $172
Current: $92.87
Upside: +85.22%
Summit Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $35
Current: $23.96
Upside: +46.08%
Arcellx
Nov 12, 2024
Maintains: Buy
Price Target: $87 → $136
Current: $57.55
Upside: +136.32%
Gilead Sciences
Nov 8, 2024
Maintains: Hold
Price Target: $83 → $97
Current: $96.91
Upside: +0.09%
Aug 16, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $0.87
Upside: +1,621.17%
Aug 9, 2024
Reiterates: Buy
Price Target: $17 → $14
Current: $1.16
Upside: +1,106.90%
Jun 24, 2024
Maintains: Buy
Price Target: $50 → $44
Current: $8.28
Upside: +431.40%
Jun 17, 2024
Initiates: Buy
Price Target: $88
Current: $31.78
Upside: +176.90%
Jun 4, 2024
Maintains: Buy
Price Target: $69 → $88
Current: $40.90
Upside: +115.16%
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $1.26
Upside: +217.46%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $0.77
Upside: +2,353.83%
Feb 29, 2024
Upgrades: Buy
Price Target: $9
Current: $0.32
Upside: +2,722.20%
Sep 6, 2023
Reiterates: Buy
Price Target: $40
Current: $1.30
Upside: +2,976.92%
Sep 6, 2023
Reiterates: Buy
Price Target: $27
Current: $0.61
Upside: +4,326.96%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $13.23
Upside: +807.03%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $1.67
Upside: +3,492.81%
Aug 23, 2022
Maintains: Buy
Price Target: $19 → $15
Current: $0.45
Upside: +3,263.23%